Xenetic Biosciences (formally Lipoxen) is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs.
The company has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Xenetic Biosciences 's technologies include: PolyXen® - Protein drug delivery, ImuXen® - DNA, protein and polysaccharide vaccines and VesicALL® - Anti-cancer drugs using liposomal entrapment.
Xenetic Biosciences hit by news of further delay in completing German acquisition
15th Dec 2011, 10:34 am by Andre Lamberti
Shares in biopharmaceuticals firm () were hit in morning trade by news that completion of the acquisition of German firm SymbioTec has been delayed again.
The deal to buy the business, a developer of technology that uses highly-alkaline proteins to treat a broad spectrum of cancers, was announced in August and was initially supposed to close in October.
It was then put back to today, December 15.
“Whilst the parties continue to work towards a conclusion … it has not been possible to satisfactorily conclude the process in the expected timeframe. The parties now expect to make a further announcement in relation to the acquisition by no later than December 31 2011,” Xenetic said today.
The stock fell on the news, and by 9.23 am, was trading down 6.9 percent at 6.751 pence.
Xenetic Bio specialises in developing high-value differentiated biologic drugs and vaccines.
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
